RETRACTION OF: A Novel Apolipoprotein E Antagonist Functionally Blocks Apolipoprotein E Interaction With N-terminal Amyloid Precursor Protein, Reduces β-Amyloid-Associated Pathology, and Improves Cognition
- 1 August 2019
- journal article
- research article
- Published by Elsevier in Biological Psychiatry
- Vol. 86 (3) , 208-220
Abstract
No abstract availableKeywords
Funding Information
- National Institute on Aging
- National Institutes of Health (R21AG049477)
- National Institutes of Health (R01AT007411)
- National Institutes of Health (R01AG050253)
This publication has 50 references indexed in Scilit:
- Soluble amyloid precursor protein-α modulates β-secretase activity and amyloid-β generationNature Communications, 2012
- Genetics: Finding risk factorsNature, 2011
- Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide ClearanceScience Translational Medicine, 2011
- Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's diseaseThe Lancet Neurology, 2011
- CD45 Deficiency Drives Amyloid-β Peptide Oligomers and Neuronal Loss in Alzheimer's Disease MiceJournal of Neuroscience, 2011
- Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapyNature Reviews Neuroscience, 2009
- Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDSJournal of Lipid Research, 2009
- Formation and Stabilization Model of the 42-mer Aβ Radical: Implications for the Long-Lasting Oxidative Stress in Alzheimer's DiseaseJournal of the American Chemical Society, 2005
- The Role of APP Processing and Trafficking Pathways in the Formation of Amyloid β‐ProteinaAnnals of the New York Academy of Sciences, 1996
- Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid proteinBiochemical and Biophysical Research Communications, 1984